Early Stage


Early Stage Pipeline

Early Stage Pipeline

Click image to expand

Earlier stage products include a novel intrathecal preparation of ketorolac and two novel non-opioid analgesic compounds with a similar mechanism of action to acetaminophen (APAP), but with the potential to be more potent and without the liver toxicity associated with APAP. Liver toxicity can be life-threatening and APAP overdose is the leading cause of acute liver failure in the U.S.1

In spite of this, APAP is an active ingredient in over 600 prescribed and over-the-counter products, including Percocet, Vicodin, Tylenol and Excedrin.

Neumentum’s products have the potential to replace APAP in the prescription and OTC markets, with superior efficacy and reduced risk of adverse effects such as liver failure.

  1. Larson AM et al. Hepatology. 2005;42(6):1364-72

Disclaimer: These are investigational new drug candidates and are not approved for any indication in any market.